Adenoviral vectored vaccination protects against Crimean-Congo Haemorrhagic Fever disease in a lethal challenge model

Saunders, Jack E.; Gilbride, Ciaran; Dowall, Stuart; Morris, Susan; Ulaszewska, Marta; Spencer, Alexandra J.; Rayner, Emma; Graham, Victoria; Kennedy, Emma; Thomas, Kelly M.; Hewson, Roger; Gilbert, Sarah C.; Belij‐Rammerstorfer, Sandra; Lambe, Teresa

doi:10.1016/j.ebiom.2023.104523

Cited by 17 publications

(11 citation statements)

References 96 publications

(121 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Complete protection against CCHFV was attained in the A129 lethal mouse model in which ChAdOx2 CCHFV was administered as a single dose or following homologous or heterologous prime-boost immunization regimens with the MVA CCHFV vaccine. However, heterologous prime-boost immunization provided a high level of protection compared with other immunization regimens in the study ( 20 ).…”

Section: Progress In Vaccine Developmentmentioning

confidence: 93%

CCHFV vaccine development, current challenges, limitations, and future directions

Ahata,

Akçapınar

2023

Front. Immunol.

View full text Add to dashboard Cite

Crimean-Congo hemorrhagic fever (CCHF) is the most prevalent tick-borne viral disease affecting humans. The disease is life-threatening in many regions of the developing world, including Africa, Asia, the Middle East, and Southern Europe. In line with the rapidly increasing disease prevalence, various vaccine strategies are under development. Despite a large number of potential vaccine candidates, there are no approved vaccines as of yet. This paper presents a detailed comparative analysis of current efforts to develop vaccines against CCHFV, limitations associated with current efforts, and future research directions.

show abstract

Section: Progress In Vaccine Developmentmentioning

confidence: 93%

CCHFV vaccine development, current challenges, limitations, and future directions

Ahata,

Akçapınar

2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…They found strong antibody responses and IFNγ-mediated cellular immunity upon administration of various vaccine combinations in both immunocompetent BALB/c and immune-deficient A129 mice. The study demonstrated that a single dose of the ChAdOx2 CCHF vaccine or homologous/heterologous primeboost vaccination regimens resulted in full protection against CCHFV-induced disease in the A129 lethal mouse model (Table 1) [175].…”

Section: Viral Vector Vaccinesmentioning

confidence: 96%

“…Recombinant viral vectors have been extensively studied as a promising vaccine platform due to their ability to express the antigens, stimulate antigen-specific immune responses, and generate potent antibody titers, all without the need for external adjuvants [169,170]. Multiple vaccine candidates have been developed for CCHF using various viral vectors, including the modified Vaccinia Ankara virus (MVA) [171,172], recombinant adenovirus type 5 (AdHu5) [173,174], recombinant chimpanzee adenovirus (ChA-dOx2) [175], recombinant vesicular stomatitis virus (rVSV) [176], and recombinant bovine herpesvirus type 4 (BoHV-4) [174].…”

Section: Viral Vector Vaccinesmentioning

confidence: 99%

Crimean–Congo Hemorrhagic Fever Virus: Progress in Vaccine Development

Özdarendeli¹

2023

Preprint

View full text Add to dashboard Cite

Crimean-Congo hemorrhagic fever virus (CCHFV), a member of the Nairoviridae family and Bunyavirales order, is transmitted to humans via tick bites or contact with the blood of infected animals. It can cause severe symptoms, including hemorrhagic fever, with a mortality rate between 5 to 30%. CCHFV is classified as a high-priority pathogen by the World Health Organization (WHO) due to its high fatality rate and the absence of effective medical countermeasures. CCHFV is endemic in several regions across the world, including Africa, Europe, the Middle East, and Asia, and has the potential for global spread. The emergence of the disease in new areas, as well as the presence of the tick vector in countries without reported cases, emphasizes the need for preventive measures should be taken. In the past, the lack of a suitable animal model susceptible to CCHFV infection has been a major obstacle in the development of vaccines and treatments. However, recent advances in biotechnology and the availability of suitable animal models have significantly expedited the development of vaccines against CCHF. These advancements have not only contributed to an enhanced understanding of the pathogenesis of CCHF but have also facilitated the evaluation of potential vaccine candidates. This review outlines of the immune response to CCHFV and animal models utilized for the study of CCHFV and highlights the progress made in CCHFV vaccine studies. Despite remarkable advancements in vaccine development for CCHFV, it remains crucial to prioritize continued research, collaboration, and investment in this field.

show abstract

“…However, in 2023 the clinical trial of the ChAdOx2 CCHF vaccine, which had promising results in animal studies was launched in the United Kingdom as the first CCHF vaccine being trialed in humans. 13 It has been indicated that antibody response is associated with the clinical outcome and the absence of antibodies in CCHF patients have been shown to be associated with bad prognosis and higher mortality rates. 6,14 Anti-CCHFV IgM and IgG antibodies are usually detectable 1 week after symptom onset, with IgG peaking in the 14−21 days of disease and persisting for up to 3 years.…”

Section: Introductionmentioning

confidence: 99%

“…Despite that several attempts have been made to design a vaccine using different platforms against CCHF, no approved effective CCHF vaccine is available. However, in 2023 the clinical trial of the ChAdOx2 CCHF vaccine, which had promising results in animal studies was launched in the United Kingdom as the first CCHF vaccine being trialed in humans 13 …”

Section: Introductionmentioning

confidence: 99%

Persistence of IgG and neutralizing antibodies in Crimean−Congo hemorrhagic fever survivors

Vasmehjani,

Pouriayevali,

Shahmahmoodi

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

The World Health Organization classified Crimean–Congo hemorrhagic fever (CCHF) as a high‐priority infectious disease and emphasized the performance of research studies and product development against it. Little information is available about the immune response due to natural CCHF virus (CCHFV) infection in humans. Here, we investigated the persistence of IgG and neutralizing antibodies in serum samples collected from 61 Iranian CCHF survivors with various time points after recovery (<12, 12−60, and >60 months after disease). The ELISA results showed IgG seropositivity in all samples while a pseudotyped based neutralization assay findings revealed the presence of neutralizing antibody in 29 samples (46.77%). For both IgG and neutralizing antibodies, a decreasing trend of titer was observed with the increase in the time after recovery. Not only the mean titer of IgG (772.80 U/mL) was higher than mean neutralizing antibody (25.64) but also the IgG persistence was longer. In conclusion, our findings provide valuable information about the long‐term persistence of humoral immune response in CCHF survivors indicating that IgG antibody can be detected at least 8 years after recovery and low titers of neutralizing antibody can be detected in CCHF survivors.

show abstract

Adenoviral vectored vaccination protects against Crimean-Congo Haemorrhagic Fever disease in a lethal challenge model

Cited by 17 publications

References 96 publications

CCHFV vaccine development, current challenges, limitations, and future directions

CCHFV vaccine development, current challenges, limitations, and future directions

Crimean–Congo Hemorrhagic Fever Virus: Progress in Vaccine Development

Persistence of IgG and neutralizing antibodies in Crimean−Congo hemorrhagic fever survivors

Contact Info

Product

Resources

About